PE20060627A1 - CONDENSED PIRAZOLE DERIVATIVES AS AGONISTS OF CANNABINOID RECEPTORS CB1 AND / OR CB2 - Google Patents
CONDENSED PIRAZOLE DERIVATIVES AS AGONISTS OF CANNABINOID RECEPTORS CB1 AND / OR CB2Info
- Publication number
- PE20060627A1 PE20060627A1 PE2005001028A PE2005001028A PE20060627A1 PE 20060627 A1 PE20060627 A1 PE 20060627A1 PE 2005001028 A PE2005001028 A PE 2005001028A PE 2005001028 A PE2005001028 A PE 2005001028A PE 20060627 A1 PE20060627 A1 PE 20060627A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- pirazole
- agonists
- cannabinoid receptors
- substituted
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical compound NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE PIRAZOL DE FORMULA I, DONDE A ES ALQUILENO C3-C5, CH2-CH2-O-CH2, ENTRE OTROS; W ES UN ENLACE DIRECTO O CH2; R1 ES H O ALQUILO C1-C3; R2 ES ALQUILO C1-C10, B-R4, ENTRE OTROS; R3 ES FENILO SUSTITUIDO CON HALOGENO, ALQUILO C1-C4, ENTRE OTROS; B ES UN ENLACE DIRECTO, ALQUILENO C1-C2, ENTRE OTROS; R4 ES FENILO NO SUSTITUIDO O SUSTITUIDO POR UNO O VARIOS SUSTITUYENTES SELECCIONADOS DE HALOGENO, ALQUILO C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-1-ADAMANTIL-1-(3,4-DICLOROFENIL)-1,4,5,6-TETRAHIDROCICLOPENTA[c]PIRAZOL-3-CARBOXAMIDA, N-[(1S)-1-CICLOHEXILETIL]-1-(3,4-DICLOROFENIL)-6,6-DIMETIL-1,4,5,6-TETRAHIDROCICLOPENTA[c]PIRAZOL-3-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS DE LOS RECEPTORES CANNABINOIDES CB1 Y/O CB2 Y SON UTILES PARA EL TRATAMIENTO DE LA MIGRANA, ESTRES, ENFERMEDADES DE ORIGEN PSICOSOMATICO, LESIONES DE MEDULA ESPINAL, ENTRE OTRASREFERRING TO A COMPOUND DERIVED FROM PIRAZOLE OF FORMULA I, WHERE A IS C3-C5, CH2-CH2-O-CH2 ALKYLENE, AMONG OTHERS; W IS A DIRECT LINK OR CH2; R1 IS H O C1-C3 ALKYL; R2 IS C1-C10 ALKYL, B-R4, AMONG OTHERS; R3 IS PHENYL SUBSTITUTED WITH HALOGEN, C1-C4 ALKYL, AMONG OTHERS; B IS A DIRECT LINK, C1-C2 ALKYLENE, AMONG OTHERS; R4 IS PHENYL NOT SUBSTITUTED OR SUBSTITUTED BY ONE OR SEVERAL SELECTED SUBSTITUTES OF HALOGEN, C1-C4 ALKYL, AMONG OTHERS. THE PREFERRED COMPOUNDS ARE: N-1-ADAMANTIL-1- (3,4-DICHLOROPHENIL) -1,4,5,6-TETRAHYDROCYCLOPENTA [c] PYRAZOL-3-CARBOXAMIDE, N - [(1S) -1-CYCLOHEXILETIL] - 1- (3,4-DICHLOROPHENYL) -6,6-DIMETHYL-1,4,5,6-TETRAHYDROCYCLOPENTA [c] PYRAZOLE-3-CARBOXAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SAID COMPOUNDS ARE AGONISTS OF CANNABINOID RECEPTORS CB1 AND / OR CB2 AND ARE USEFUL FOR THE TREATMENT OF MIGRANA, STRESS, DISEASES OF PSYCHOSOMATIC ORIGIN, SPINAL CORD INJURIES, AMONG OTHERS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0409712A FR2875230A1 (en) | 2004-09-13 | 2004-09-13 | CONDENSED PYRAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060627A1 true PE20060627A1 (en) | 2006-08-15 |
Family
ID=34954413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001028A PE20060627A1 (en) | 2004-09-13 | 2005-09-06 | CONDENSED PIRAZOLE DERIVATIVES AS AGONISTS OF CANNABINOID RECEPTORS CB1 AND / OR CB2 |
Country Status (6)
| Country | Link |
|---|---|
| AR (1) | AR051288A1 (en) |
| FR (1) | FR2875230A1 (en) |
| PE (1) | PE20060627A1 (en) |
| TW (1) | TW200621786A (en) |
| UY (1) | UY29112A1 (en) |
| WO (1) | WO2006030124A1 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| AU2006253842A1 (en) * | 2005-06-02 | 2006-12-07 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| WO2007001939A1 (en) * | 2005-06-27 | 2007-01-04 | Janssen Pharmaceutica N.V. | Tetrahydro-pyranopyrazole compounds displaying cannabinoid modulating activities |
| US8378096B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| US8378117B2 (en) * | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
| AU2006292051B2 (en) * | 2005-09-23 | 2012-11-15 | Janssen Pharmaceutica, N.V. | Tetrahydro-cyclopentyl pyrazole cannabinoid modulators |
| AU2006295130A1 (en) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica, N.V. | Tetrahydro-indazolyl cannabinoid modulators |
| DK1931335T3 (en) | 2005-09-23 | 2010-06-07 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
| US7825151B2 (en) | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
| JP2009508953A (en) * | 2005-09-23 | 2009-03-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Hexahydro-cycloheptopyrazole cannabinoid modulator |
| WO2007095513A1 (en) * | 2006-02-14 | 2007-08-23 | Janssen Pharmaceutica, Nv | Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators |
| US20070254911A1 (en) * | 2006-03-27 | 2007-11-01 | Mingde Xia | Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators |
| EP2139326A4 (en) * | 2007-03-21 | 2011-06-15 | Janssen Pharmaceutica Nv | Method for treating cb2 receptor mediated pain |
| AU2008229265A1 (en) * | 2007-03-21 | 2008-09-25 | Janssen Pharmaceutica N.V. | Method for treating CB2 receptor mediated pain |
| EP2269990A4 (en) * | 2008-03-25 | 2012-04-18 | Takeda Pharmaceutical | HETEROCYCLIC COMPOUND |
| WO2010088050A2 (en) * | 2009-01-28 | 2010-08-05 | Cara Therapeutics, Inc. | Bicyclic pyrazolo-heterocycles |
| CN102596913B (en) * | 2009-08-28 | 2016-11-09 | 艾尼纳制药公司 | Cannabinoid Receptor Modulators |
| DK3252057T3 (en) | 2009-12-04 | 2024-06-17 | Sunovion Pharmaceuticals Inc | MULTICYCLIC COMPOUNDS AND METHODS OF USING THEREOF |
| ES2929977T3 (en) | 2011-02-25 | 2022-12-05 | Arena Pharm Inc | Cannabinoid receptor modulators |
| WO2012116277A1 (en) | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| WO2012116278A1 (en) * | 2011-02-25 | 2012-08-30 | Arena Pharmaceuticals, Inc. | Cannabinoid receptor modulators |
| BR112013021549B1 (en) | 2011-02-25 | 2022-01-11 | Arena Pharmaceuticals, Inc | PROCESSES FOR PREPARATION OF CRYSTALLINE ANHYDROUS FORM, FOR PREPARATION OF PHARMACEUTICAL COMPOSITION AND FOR PREPARATION OF DOSAGE FORM, NON-SOLVATED CRYSTALLINE ANHYRED FORM, PHARMACEUTICAL COMPOSITION, DOSAGE FORM, USE OF SUCH CRYSTALLINE FORM AND SOLVATE |
| EP2847180B1 (en) * | 2012-05-11 | 2017-01-04 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| US20190016680A1 (en) | 2016-01-14 | 2019-01-17 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| CN116283877A (en) | 2016-07-29 | 2023-06-23 | 赛诺维信制药公司 | Compounds, compositions and uses thereof |
| AU2017301767A1 (en) | 2016-07-29 | 2019-02-14 | Pgi Drug Discovery Llc | Compounds and compositions and uses thereof |
| CN110678205B (en) | 2017-02-16 | 2023-05-23 | 桑诺维恩药品公司 | Methods of treating schizophrenia |
| EA201992638A1 (en) | 2017-05-08 | 2020-03-18 | Арена Фармасьютикалз, Инк. | COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN |
| KR20200036008A (en) | 2017-08-02 | 2020-04-06 | 선오비온 파마슈티컬스 인코포레이티드 | Isocroman compounds and uses thereof |
| JP7453148B2 (en) | 2018-02-16 | 2024-03-19 | サノビオン ファーマシューティカルズ インク | Salts, crystalline forms, and their production methods |
| MX2021010880A (en) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | SALTS OF AN ISOCHROMANIL COMPOUND AND CRYSTALLINE FORMS, PREPARATION PROCESSES, THERAPEUTIC USES AND PHARMACEUTICAL COMPOSITIONS THEREOF. |
| WO2021047583A1 (en) * | 2019-09-12 | 2021-03-18 | 四川海思科制药有限公司 | Tricyclic pyrazole derivative and preparation thereof |
| WO2021047581A1 (en) * | 2019-09-12 | 2021-03-18 | 四川海思科制药有限公司 | Hexahydrobenzopyrazole derivative and preparation therefof |
| MX2022012833A (en) | 2020-04-14 | 2022-11-07 | Sunovion Pharmaceuticals Inc | (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2742148B1 (en) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2800375B1 (en) * | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | TRICYCLIC DERIVATIVES OF PYRAZOLECARBOXYLIC ACID, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| JP2004502642A (en) * | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | Cannabinoid receptor modulators, methods for their production, and use of cannabinoid receptor modulators for the treatment of respiratory and non-respiratory diseases |
| EP1448557A4 (en) * | 2001-10-26 | 2005-02-02 | Univ Connecticut | HETEROINDANES: NEW CLASS OF EFFECTIVE CANNABIMIMETIC LIGANDS |
| TW200602324A (en) * | 2004-03-24 | 2006-01-16 | Janssen Pharmaceutica Nv | Tetrahydro-indazole cannabinoid modulators cross reference to related applications |
-
2004
- 2004-09-13 FR FR0409712A patent/FR2875230A1/en not_active Withdrawn
-
2005
- 2005-09-06 PE PE2005001028A patent/PE20060627A1/en not_active Application Discontinuation
- 2005-09-09 UY UY29112A patent/UY29112A1/en not_active Application Discontinuation
- 2005-09-09 AR ARP050103775A patent/AR051288A1/en not_active Application Discontinuation
- 2005-09-12 WO PCT/FR2005/002255 patent/WO2006030124A1/en not_active Ceased
- 2005-09-12 TW TW094131307A patent/TW200621786A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006030124A1 (en) | 2006-03-23 |
| UY29112A1 (en) | 2006-04-28 |
| TW200621786A (en) | 2006-07-01 |
| AR051288A1 (en) | 2007-01-03 |
| FR2875230A1 (en) | 2006-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060627A1 (en) | CONDENSED PIRAZOLE DERIVATIVES AS AGONISTS OF CANNABINOID RECEPTORS CB1 AND / OR CB2 | |
| PE20070519A1 (en) | DERIVATIVES OF PHENYLMORPHOLINE AND PHENYLTIOMORPHOLINE AS AGONISTS OF ALPHA 2C ADRENORECEPTORS | |
| EA200501504A1 (en) | Cannabinoid receptor ligands and their use | |
| PE20070336A1 (en) | INDOLINE COMPOUNDS AS AGONISTS OF FUNCTIONALLY SELECTIVE ALFA2C ADRENERGIC RECEPTORS | |
| UA84022C2 (en) | Carbamoylcyclohexane Derived (Thio) As Receptor D3 / D2 Antagonists | |
| PE20040164A1 (en) | MIMETICS OF GLUCOCORTICOIDS, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | |
| EA200401282A1 (en) | PYRIDINOILPIPERIDINES AS 5-HT1F AGONISTS | |
| EA200301073A1 (en) | N- (2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF 5-HT RECEPTOR | |
| DE602005020655D1 (en) | Carboxamide-spirolactam CGRP Receptor Antagonists | |
| EA200300453A1 (en) | 3-AROYLINDOL DERIVATIVES AND THEIR APPLICATION AS AGONISTS OF CB2 RECEPTORS | |
| PA8546601A1 (en) | NEW INDOL DERIVATIVES WITH AFFINITY FOR THE 5-HT6 RECEIVER | |
| PE20040946A1 (en) | PYRAZOLOTRIAZINE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | |
| PA8547901A1 (en) | 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | |
| ATE496620T1 (en) | 1H-BENZO(F)INDAZOLE-5-YL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | |
| PE20091376A1 (en) | DERIVATIVES OF PHENYLAMINE AS BETA-AMYLOID MODULATORS | |
| AR051461A1 (en) | PIRAZOLO COMPOUND [1,5-A] PIRIMIDIN-7-IL-AMINA POLYFORM FORM 1 OF [3- (4-METOXI-2-METHYL-PHENYL) -2,5-DIMETIL-PIRAZOLO [1,5-A] PIRIMIDIN-7-IL] - [(S) -1- (3-METHYL- [1,2,4] OXADIAZOL-5-IL) -PROPIL] -AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE IT | |
| EA200300829A1 (en) | Derivatives of 1-aryl-or 1-alkylsulfonylbenzene as a ligand 5-hydroxytriptamine-6 | |
| DE602004012858D1 (en) | 2-AMINOBENZOTHIAZOLE AS CB1 RECEPTOR INVERSE AGONISTS | |
| NO20071476L (en) | Antidiuretic agents. | |
| PA8581401A1 (en) | IMEDAZOPIRIDINE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS | |
| PE20140968A1 (en) | SUBSTITUTED BENZAMIDE DERIVATIVES | |
| PE20060625A1 (en) | BENZAZEPINE DERIVATIVES AS ANTAGONISTS AND / OR AGONISTS OF THE HISTAMINE H3 RECEPTOR | |
| PE20081781A1 (en) | FUNCTIONALLY SELECTIVE ALFA2C ADRENORECEPTOR AGONISTS | |
| PE20071224A1 (en) | AMINOMETHYLPYRIDINE DERIVATIVES AS ANTAGONISTS OF CANNABINOID RECEPTORS 1 (CB1) | |
| EA200301143A1 (en) | DERIVATIVES OF HETEROCYCLILALKOXY-, ALKYLTIO-AND-ALKYLAMINOBENZENOLE AS 5-HYDROXITRIPTAMINE-6 LIGANDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |